135 related articles for article (PubMed ID: 19948880)
1. Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Park JW; Ma SK; Lee JU; Kim SW
Nephrol Dial Transplant; 2010 Apr; 25(4):1051-9. PubMed ID: 19948880
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Hypertens Res; 2010 Mar; 33(3):255-62. PubMed ID: 20057489
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effects of sildenafil in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Joo SY; Kim EY; Kim CS; Choi JS; Ma SK; Kim SH; Lee JU; Kim SW
Kidney Blood Press Res; 2012; 36(1):248-57. PubMed ID: 23171857
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Bae EH; Kim IJ; Song JH; Choi HS; Kim CS; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691015
[TBL] [Abstract][Full Text] [Related]
5. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats.
Kagitani S; Ueno H; Hirade S; Takahashi T; Takata M; Inoue H
J Hypertens; 2004 May; 22(5):1007-15. PubMed ID: 15097242
[TBL] [Abstract][Full Text] [Related]
6. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.
Ishimaru K; Ueno H; Kagitani S; Takabayashi D; Takata M; Inoue H
J Cardiovasc Pharmacol; 2007 Aug; 50(2):187-94. PubMed ID: 17703135
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats.
Elmarakby AA; Quigley JE; Imig JD; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2008 Jan; 294(1):R76-83. PubMed ID: 17989143
[TBL] [Abstract][Full Text] [Related]
8. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
Ndisang JF; Jadhav A
J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
[TBL] [Abstract][Full Text] [Related]
9. Tumor Necrosis Factor Alpha Deficiency Improves Endothelial Function and Cardiovascular Injury in Deoxycorticosterone Acetate/Salt-Hypertensive Mice.
Cai R; Hao Y; Liu YY; Huang L; Yao Y; Zhou MS
Biomed Res Int; 2020; 2020():3921074. PubMed ID: 32190663
[TBL] [Abstract][Full Text] [Related]
10. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism.
Ammarguellat F; Larouche I; Schiffrin EL
Circulation; 2001 Jan; 103(2):319-24. PubMed ID: 11208696
[TBL] [Abstract][Full Text] [Related]
11. Dietary Potassium Supplementation Reduces Chronic Kidney Lesions Independent of Blood Pressure in Deoxycorticosterone-Acetate and High Sodium Chloride-Treated Mice.
Wang Q; Schäfer SC; Haefliger JA; Maillard MP; Alonso F
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069178
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
[TBL] [Abstract][Full Text] [Related]
13. Detrimental role of sphingosine kinase 1 in kidney damage in DOCA-salt hypertensive model: evidence from knockout mice.
Lyu B; Wang W; Ji XY; Ritter JK; Li N
BMC Nephrol; 2020 May; 21(1):173. PubMed ID: 32393187
[TBL] [Abstract][Full Text] [Related]
14. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension.
Hartner A; Klanke B; Cordasic N; Amann K; Schmieder RE; Veelken R; Hilgers KF
J Hypertens; 2009 Feb; 27(2):376-85. PubMed ID: 19226708
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Loch D; Levick S; Hoey A; Brown L
J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
[TBL] [Abstract][Full Text] [Related]
16. Correlation between platelet-derived growth factor signaling pathway and inflammation in desoxycorticosterone-induced salt-sensitive hypertensive rats with myocardial fibrosis.
Fan B; Ma L; Li Q; Wang L; Zhou J; Wu J
Int J Clin Exp Pathol; 2013; 6(11):2468-75. PubMed ID: 24228109
[TBL] [Abstract][Full Text] [Related]
17. Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension.
Wang Y; Wang DH
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1550-9. PubMed ID: 19794112
[TBL] [Abstract][Full Text] [Related]
18. Effect of pravastatin on nephroprotection in deoxycorticosterone acetate-salt hypertensive rats.
Kang CS; Chang NC; Chang ST; Lin CC; Lee TM
J Hypertens; 2009 Nov; 27(11):2232-43. PubMed ID: 19812503
[TBL] [Abstract][Full Text] [Related]
19. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
20. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
